1. Diren Beyoğlu is a PhD pharmacist, toxicologist and research fellow working in J Idle’s group and in collaboration with the US National Cancer Institute on mass spectrometry-based discovery metabolomics and the definition of metabolomic biomarkers of clinical relevance. Currently, her research focuses on metabolomic insights into hepatobiliary diseases.
2. Jeffrey R Idle is Visiting Professor in the Hepatology Research Group at the University of Bern (Switzerland). In 1977 he was the codiscoverer of the CYP2D6 genetic polymorphism in debrisoquine 4-hydroxylation. His research is centered on metabolomics using various mass spectrometry platforms and the broad application of the findings to medicine.